Boehringer Ingelheim Vetmedica, Inc., is furthering its commitment to research efforts to ensure that we continue to learn more about equine diseases by entering the first year of the Annual Boehringer Ingelheim Advancement in Equine Research Award Program.
Scientists, researchers, practicing veterinarians, animal health companies, and horse owners have long been dedicated to improving the health of the horse. Yet the need for more knowledge in regards to disease prevention, lameness and general wellness still exists.
The BIVI Equine Research Award will focus on one specific equine disease area each year. For 2011 the equine disease of focus is Equine Rhinitis Virus (ERV). Specifically, four areas of interest within ERV have been identified:
- Pathophysiology of ERV In the horse.
- Incidence and implications of co-infection with ERV and other equine respiratory pathogens.,
- Incidence of ERV related to geographical location and equine discipline.
- Acute/chronic effects of ERV on the lower airway disease in the horse.
Boehringer Ingelheim is providing three $25,000 awards to the winning proposals for Rhinitis research in the US and Canada. Candidates include graduate students, academic researchers, company or private researchers, and practicing veterinarians. Winning proposals will be selected by an independent review board.
The 2011 Advancement in Equine Research Awards recipients will be announced at the American Association of Equine Practitioners Conference in San Antonio, Texas, November 18-22, 2011.
Once the three winning year-long research projects are completed and submitted for peer review, the Equine Research Review Board will conduct a second evaluation. Upon acceptance for publication of his or her findings, the first place award recipient will receive an additional U.S. $5,000; second place, $3,000; and third place, $1,000.